Regeneron (NASDAQ:REGN) and non-U.S. commercialization partner Bayer (OTC:BAYRY) got some great news last week, when the European Committee for Medicinal Products for Human Use (CHMP) recommended its eye drug Eylea for approval for the treatment of visual impairment due to diabetic macular edema (DME). It's a big potential follow-on indication (as many as 6.2 million people) for a drug that's already been approved and made just under $2 billion in sales last year.

This is a drug that analysts estimate could bring in as much as $4.7 billion annually in peak sales for Regeneron.

In the video below, Motley Fool health care analysts Michael Douglass and David Williamson lay out Regeneron's exciting prospects for this drug.